Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US

被引:0
作者
Hui Shao
Abdul Jabbar Omar Alsaleh
Terry Dex
Elisheva Lew
Vivian Fonseca
机构
[1] University of Florida’s College of Pharmacy,
[2] Sanofi,undefined
[3] Sanofi,undefined
[4] Sanofi,undefined
[5] Tulane University School of Medicine,undefined
[6] Tulane University Health Sciences Center,undefined
来源
Diabetes Therapy | 2022年 / 13卷
关键词
BIAsp 30; Cost-effectiveness; Cost-utility; iGlarLixi; Older adults; Premix; SoliMix trial; Type 2 diabetes; United States;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1659 / 1670
页数:11
相关论文
共 82 条
[1]  
Bommer C(2018)Global economic burden of diabetes in adults: projections from 2015 to 2030 Diabetes Care 41 963-970
[2]  
Sagalova V(2018)Diabetes management in the elderly Diabetes Spectrum 31 245-253
[3]  
Heesemann E(2018)Basal insulin intensification in patients with type 2 diabetes: a review Diabetes Ther 9 877-890
[4]  
Leung E(2005)Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens J Gen Intern Med 20 479-482
[5]  
Wongrakpanich S(2012)Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study Diabet Med 29 682-689
[6]  
Munshi MN(2004)The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making Curr Med Res Opin 20 S5-26
[7]  
Meece J(2014)Validation of the IMS CORE diabetes model Value Health 17 714-724
[8]  
Vijan S(2018)Computer modeling of diabetes and its transparency: a report on the eighth mount hood challenge Value Health 21 724-731
[9]  
Hayward RA(2013)UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82 Diabetologia 56 1925-1933
[10]  
Ronis DL(2016)Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine JAMA 316 1093-1103